Annual Cash & Cash Equivalents
$143.43 M
-$122.03 M-45.97%
December 31, 2024
Summary
- As of March 7, 2025, IBRX annual cash & cash equivalents is $143.43 million, with the most recent change of -$122.03 million (-45.97%) on December 31, 2024.
- During the last 3 years, IBRX annual cash & cash equivalents has fallen by -$37.67 million (-20.80%).
- IBRX annual cash & cash equivalents is now -45.97% below its all-time high of $265.45 million, reached on December 31, 2023.
Performance
IBRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$143.43 M
+$31.46 M+28.10%
December 31, 2024
Summary
- As of March 7, 2025, IBRX quarterly cash and cash equivalents is $143.43 million, with the most recent change of +$31.46 million (+28.10%) on December 31, 2024.
- Over the past year, IBRX quarterly cash and cash equivalents has increased by +$31.46 million (+28.10%).
- IBRX quarterly cash and cash equivalents is now -45.97% below its all-time high of $265.45 million, reached on December 31, 2023.
Performance
IBRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
IBRX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -46.0% | +28.1% |
| 3 y3 years | -20.8% | +28.1% |
| 5 y5 years | - | +28.1% |
IBRX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -46.0% | +37.1% | -46.0% | +294.2% |
| 5 y | 5-year | -46.0% | +310.8% | -46.0% | +310.8% |
| alltime | all time | -46.0% | +310.8% | -46.0% | +310.8% |
ImmunityBio Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $143.43 M(-46.0%) | $143.43 M(+28.1%) |
| Sep 2024 | - | $111.97 M(-13.9%) |
| Jun 2024 | - | $130.10 M(-2.2%) |
| Mar 2024 | - | $133.03 M(-49.9%) |
| Dec 2023 | $265.45 M(+153.7%) | $265.45 M(+49.2%) |
| Sep 2023 | - | $177.96 M(+309.1%) |
| Jun 2023 | - | $43.51 M(-50.8%) |
| Mar 2023 | - | $88.48 M(-15.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2022 | $104.64 M(-42.2%) | $104.64 M(+0.5%) |
| Sep 2022 | - | $104.16 M(+68.3%) |
| Jun 2022 | - | $61.90 M(+70.1%) |
| Mar 2022 | - | $36.38 M(-79.9%) |
| Dec 2021 | $181.10 M(+418.7%) | $181.10 M(+180.7%) |
| Sep 2021 | - | $64.52 M(-23.1%) |
| Jun 2021 | - | $83.96 M(+87.9%) |
| Mar 2021 | - | $44.68 M(+28.0%) |
| Dec 2020 | $34.91 M | $34.91 M |
FAQ
- What is ImmunityBio annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ImmunityBio?
- What is ImmunityBio annual cash & cash equivalents year-on-year change?
- What is ImmunityBio quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for ImmunityBio?
- What is ImmunityBio quarterly cash and cash equivalents year-on-year change?
What is ImmunityBio annual cash & cash equivalents?
The current annual cash & cash equivalents of IBRX is $143.43 M
What is the all time high annual cash & cash equivalents for ImmunityBio?
ImmunityBio all-time high annual cash & cash equivalents is $265.45 M
What is ImmunityBio annual cash & cash equivalents year-on-year change?
Over the past year, IBRX annual cash & cash equivalents has changed by -$122.03 M (-45.97%)
What is ImmunityBio quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of IBRX is $143.43 M
What is the all time high quarterly cash and cash equivalents for ImmunityBio?
ImmunityBio all-time high quarterly cash and cash equivalents is $265.45 M
What is ImmunityBio quarterly cash and cash equivalents year-on-year change?
Over the past year, IBRX quarterly cash and cash equivalents has changed by +$31.46 M (+28.10%)